-

Talaris Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, is scheduled to virtually present at the 39th Annual J.P. Morgan Healthcare Conference. Chief Executive Officer Scott Requadt will present a company overview on Monday, January 11, 2021 at 9:15 a.m. ET.

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Talaris is backed by a number of leading life sciences investors and maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky. www.TalarisTx.com.

Contacts

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Industry:

Talaris Therapeutics, Inc.

Release Versions
English

Contacts

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

More News From Talaris Therapeutics, Inc.

Talaris Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer

BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a late- clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune or metabolic disorders, today announced the appointment of Mary Kay Fenton as Chief Financial Officer. “Mary Kay is an important addition to Talaris’ executive team. She brings great leadership a...

Talaris Therapeutics Appoints Four Vice Presidents in Areas of Strategic Importance

BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris today announced the appointment of four vice presidents in areas of strategic importance for the company....

Talaris Therapeutics Adds Two Experienced Biotechnology Executives to its Board of Directors

BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the appointment of Sapna Srivastava, Ph.D., and Gaurav Shah, M.D., as independent representatives to its Board of Directors. “Sapna and Gaurav are both experienced biotechnology leaders with deep industry knowledge and a track record of value...
Back to Newsroom